Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN2222 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Reference Drug | EXPERIMENTAL | REGN2222 Reference Formulation |
| Test Drug | EXPERIMENTAL | REGN2222 Test Formulation |
| Cohort 1 | EXPERIMENTAL | Dosing regimen 1 |
| Cohort 2 | EXPERIMENTAL | Dosing regimen 2 |
| Cohort 3 | EXPERIMENTAL | Dosing regimen 3 |
| Cohort 4 | EXPERIMENTAL | Dosing regimen 4 |
| Cohort 5 | EXPERIMENTAL | Dosing regimen 5 |
| Name | Type | Description |
|---|---|---|
| REGN2222 | DRUG | - |
| REGN2222(SAR438584) | DRUG | - |
| placebo | DRUG | - |
Key Inclusion Criteria: 1. Healthy man or woman aged 18 to 60 years 2. Body weight between 50.0 kg and 95.0 kg, inclusive 3. Willing and able to comply with clinic visits and study-related procedures 4. Provide signed informed consent Key Exclusion Criteria: 1. Hemoglobin not within normal limits...
REGN2222 is an investigational small molecule being studied in healthy volunteers. It is in Phase 1 clinical development, with completed trials assessing its safety, tolerability, and blood concentrations. It is not approved for any condition and remains in early-stage clinical testing.
REGN2222 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker REGN. The company is conducting Phase 1 studies of this investigational small molecule in healthy volunteers.
REGN2222 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug is investigational and has not been approved by regulatory authorities, as it is still in early-stage clinical testing.
REGN2222 has two completed Phase 1 trials. NCT02121080 studied safety and tolerability in 132 healthy adults, and NCT02828397 studied blood concentrations of two formulations in 28 healthy subjects. Both trials were conducted in the United States with participants aged 18 years and older.
Yes, REGN2222 is also known as SAR438584. The first clinical trial, NCT02121080, is titled 'Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers,' confirming that both names refer to the same investigational drug.